研究文章

比较疗效和安全性Teriflunomide与富马酸二甲酯的复发缓和多发性硬化治疗

表1

人口统计学和临床信息匹配之前和之后的研究团体。

变量 所有的病人 匹配的组
DMF (N= 70) 扶轮基金会(N= 79) 统计数据 DMF (N= 38) 扶轮基金会(N= 38) 统计数据

在疾病发病年龄y意思是(SD) 25.17±7.23 32.28±10.06 MD = 7.10,t(145)= 4.859, < 0.001 27.52±6.96 28.56±9.11 MD = 1.04,t(67.41)= 0.555, = 0.581
年龄在最后访问,y意思是(SD) 29.47±8.18 40.72±10.21 MD = 11.25,t(147)= 7.354, < 0.001 33.15±7.74 34.92±9.18 MD = 1.76,t(74)= 0.905, = 0.369
女,n(%) 57 (81.4%) 68例(86.1%) X2(N= 149,df = 1) = 0.593, = 0.441 32 (84.2%) 33 (86.8%) X2(N= 76,df = 1) = 0.106, = 0.744
教育水平、n(%) 非学术 25 (35.7%) 47 (59.5%) X2(N= 149,df = 1) = 8.404, = 0.004 22 (57.9%) 22 (57.9%) X2(N= 76,df = 1) = 7.773, = 0.005
学术 45 (64.3%) 32 (40.5%) 16 (42.1%) 16 (42.1%)
就业状况,n(%) 就业 26日(37.1) 26 (37.1%) X2(N= 149,df = 1) = 0.177, = 0.674 14 (36.8%) 15 (39.5%) X2(N= 76,df = 1) = 0.056, = 0.813
失业 44 (62.9%) 32 (40.5%) 24 (63.2%) 23 (60.5%)
第一个表现,n(%) 视觉 18 (25.7%) 28 (35.4%) X2(N= 149,df = 1) = 2.435, = 0.296 13 (34.2%) 13 (34.2%) X2(N= 70,df = 1) = 0.500, = 0.779
电动机 29 (41.4%) 37 (46.8%) 18 (47.2%) 19 (50.0%)
大脑和脑干 13 (18.6%) 9 (11.4%) 6 (15.8%) 6 (15.8%)
DMT治疗扶轮基金会/ DMF治疗开始前,n(%) 32 (45.7%) 47 (59.5%) X2(N= 149,df = 1) = 2.829, = 0.093 24 (63.2%) 24 (63.2%) X2(N= 76,df = 1) = 0.000, = 1.000
疾病持续时间,y中位数(差) 3.5 (1.0 - -6.0) 6.0 (2.0 - -12.0) U= 1719, < 0.001 5.0 (1.7 - -8.2) 5.0 (2.0 - -10.2) U= 705.5, = 0.863
eds扶轮基金会/ DMF治疗开始前,中值(差) 1.5 (0.0 - -2.0) 2.0 (1.0 - -2.0) U= 2555.5, = 0.403 1.25 (0.0 - -2.0) 1.5 (0.0 - -2.0) U= 697.0, = 0.787
在36个月内复发扶轮基金会/ DMF治疗开始前,意味着(SD) 0.71±0.54 0.56±0.52 MD =−0.14,t(147)=−1.656, = 0.100 0.65±0.58 0.63±0.54 MD = -0.02,t(74)= -0.204, = 0.839
至少有一个在36个月内复发患者扶轮基金会/ DMF治疗开始前,n(%) 47 (67.2%) 44 (55.7%) X2(N= 149,df = 1) = 2.045, = 0.153 23 (60.6%) 23 (60.6%) X2(N= 76,df = 1) = 0.000, = 1.000
在12个月内复发扶轮基金会/ DMF治疗开始前,意味着(SD) 0.31±0.46 0.15±0.39 MD =−0.16,t(147)=−2.297, = 0.025 0.26±0.44 0.23±0.48 MD = -0.02,t(74)= -0.245, = 0.807
至少有一个患者在12个月内复发扶轮基金会/ DMF治疗开始前,n(%) 22 (31.4%) 11 (14.1) X2(N= 149,df = 1) = 6.595, = 0.010 10 (26.3%) 8 (21.1%) X2(N= 76,df = 1) = 0.291, = 0.589

DMF:富马酸二甲酯;扶轮基金会:teriflunomide;DMT:疾病修饰治疗;eds:扩大残疾状态量表;MD:平均差。